

Occurrence and antimicrobial susceptibility of thermophilic *Campylobacter* species isolated from healthy children attending municipal care centers in Southern Ecuador

Zorayda Toledo¹, Rosa Janneth Simaluiza¹, Xavier Astudillo¹, Heriberto Fernández²

ABSTRACT

The prevalence and antimicrobial susceptibility of *Campylobacter jejuni* and *C. coli* strains in healthy, well-nourished children of middle socioeconomic level from Southern Ecuador were determined. Among the 127 children studied, 17 (13.4%) harbored *Campylobacter* sp. corresponding to *C. jejuni* (7.1%) and *C. coli* (6.3%) with a higher concentration of *C. jejuni* among boys (8.6%) and *C. coli* (8.8%) among girls. *C. jejuni* showed high resistance to nalidixic acid and ciprofloxacin (77.8%), but susceptibility to all other antimicrobials tested. *C. coli* strains showed resistance to more antibiotics than *C. jejuni* strains including resistance to nalidixic acid (75%), ciprofloxacin (75%), erythromycin (12.5%) and ampicillin (28.6), but susceptible to gentamicin and amoxicillin/clavulanic acid.

KEYWORDS: *Campylobacter*. Healthy carriers. Children. Antimicrobials. Ecuador. *Campylobacter jejuni*, *Campylobacter coli*, *Campylobacter* resistance and susceptibility to antibiotics

Currently, the genus *Campylobacter* comprises 27 species and 12 subspecies. They are considered as ubiquitous bacteria frequently found in the intestinal tract of a wide range of animals, including birds, mammals and reptiles, which are also recognized as reservoir for these bacteria¹⁻³.

Several *Campylobacter* species have been reported as infectious agents for humans in both, industrialized and developing countries, being the thermophilic *Campylobacter* species - *C. jejuni*, *C. coli*, *C. lari* and *C. upsaliensis* - most commonly associated with human infections, especially with acute infectious diarrhea. However, they could also produce extra-intestinal infections and severe complications leading to sequelae such as Guillain-Barré or Miller Fisher Syndromes^{4,5}.

Campylobacter gastroenteritis is a major public health problem with increasing rates worldwide, being the most common cause of bacterial diarrhea in developed countries and the second or third cause in developing countries, particularly in South America^{3,6,7}. The available clinical, laboratory and epidemiological data have been produced mainly in developed countries, where national surveillance programs for campylobacteriosis exist⁸. In general, developing countries do not have this kind of programs or they are just implementing them, which does not allow reliable and conclusive epidemiological data⁹. On the other hand, in developing countries, *Campylobacter* is not routinely diagnosed as enteric pathogens, thus, their frequency in infant community-acquired diarrhea is commonly underestimated¹⁰.

Campylobacter isolation rates in diarrheic patients from developing countries

⁽¹⁾Universidad Técnica Particular de Loja, Departamento de Ciencias de la Salud, sección de Genética Humana, Microbiología y Bioquímica Clínica, Loja, Ecuador

⁽²⁾Universidad Austral de Chile, Instituto de Microbiología Clínica, Valdivia, Región de Los Ríos, Chile

Correspondence to: Heriberto Fernández
Universidad Austral de Chile, Instituto de Microbiología Clínica, Edificio de Ciencias Biomédicas, Campus Isla Teja Valdivia, Región de Los Ríos, 5090000, Chile
Tel: +56 63 2214377, +56 63 2293300

E-mail: hfernand@uach.cl

Received: 16 May 2017

Accepted: 28 July 2017

range from 5 to 23%^{7,8}. Isolation of *Campylobacter* from children without diarrhea in those countries seems to be a frequent epidemiological fact^{7,11} but it is not well-documented in many of them as to allow real epidemiological data. Moreover, in developing countries, *Campylobacter* is a common cause of diarrheal disease among children at risk for growth failure¹².

Among children, *Campylobacter* infections are mainly responsible for digestive manifestations especially acute diarrhea and in a lesser extent, chronic or recurrent diarrhea. More rarely, immune-mediated complications (reactive arthritis and Guillain Barré syndrome) and extra intestinal infections like bacteremia can occur^{13,14}.

Campylobacter gastroenteritis in humans is considered a zoonotic foodborne illness^{6,7}. In the last years, over 40% of laboratory-confirmed *Campylobacter* strains were resistant to several antimicrobials, mainly to tetracyclines, quinolones and macrolides, limiting treatment options^{6,7}. In developing countries, high resistance levels have been found among *Campylobacter* strains isolated from intestinal and extra-intestinal infections in children¹⁴⁻¹⁶.

The aim of this descriptive study, performed during five months, from May to September 2016, was to determine the occurrence and antimicrobial susceptibility of thermophilic *Campylobacter* species in healthy well-nourished children of middle socioeconomic level in Southern Ecuador.

Stool samples were obtained from each of 127 children who attended municipal day-care centers of Loja city (3°59' Lat S; 79°12' Long W). Children aged 1–16 years with median age of 7.2 years, being 57 females and 70 males. Parents of all study participants provided written informed consent and the study was approved by the Ethics Committee of the *Universidad Técnica Particular de Loja*.

Once obtained, each stool sample was seeded into the semisolid TEM (transport enrichment medium) described by Fernández¹⁷ consisting of Brucella broth 28 g, agar 1.5 g, sodium metabisulphite 0.5 g, ferrous sulfate 0.5 g, sodium pyruvate 0.5 g, trimethoprim 10 mg, rifampicin 15 mg, colistin 10,000 IU, amphotericin 10 mg and defibrinated horse blood 30 mL (formula/L) and transported to the laboratory. Following an enrichment period of 24 h at 42 °C under microaerobic conditions obtained using generator envelopes (Oxoid), sample aliquots were seeded onto Butzler's medium plates that were incubated for 48 h under the same conditions described above. Suspected colonies were identified morphologically (Gram stain), biochemically (oxidase, catalase, sensitivity to nalidixic acid and cephalothin, hippurate and indoxyl acetate hydrolysis) and confirmed by the multiplex PCR test proposed by Yamazaki-Matsune *et al.*¹⁸. In brief, after extraction of genomic DNA, 5 µL of template DNA were

added to a mixture containing 2 µM of each primer and 25 µL of 2x Multiplex PCR Master Mix (QIAGEN, USA) adjusting final volume to 50 µL with RNase-free H₂O. DNA amplification was performed in thermocycler (Eppendorf) using the following cycling conditions: one cycle of initial denaturation at 95 °C for 15 min., followed by 25 cycles of denaturation at 95 °C for 0.5 min; annealing was done at 58 °C for 1.5 min and extension at 72 °C for 1 min, ending with a final extension time at 72 °C for 7 min. Reaction mixtures were analyzed by gel electrophoresis (3% w/v agarose) stained with ethidium bromide and visualized under UV transilluminator.

Susceptibility to ampicillin (10 µg), amoxicillin/clavulanic acid (20/10 µg), erythromycin (15 µg), ciprofloxacin (5 µg), nalidixic acid (30 µg), tetracycline (30 µg) and gentamycin (10 µg) was determined by the disk diffusion method following the 2014 recommendations of The European Committee on Antimicrobial Susceptibility Testing-EUCAST and the Antibiogram Committee of the French Microbiology Society¹⁹ using Müller-Hinton agar supplemented with 5% horse blood and 20 mg/L of β-NAD. Inocula were prepared suspending several well-isolated colonies of each strain in sterile saline buffer (NaCl 0.9%) until obtaining a turbidity equal to 0.5 McFarland nephelometer. Suspensions were seeded on the plates using soaked swabs and after allowing to dry, antibiotic discs were placed on the plates. After 24 h of incubation under microaerobic conditions at 37 °C, diameters of the inhibition zones were measured to establish resistance (R) and susceptibility (S) in accordance with the breakpoints proposed by EUCAST (ampicillin R < 14 mm, S = 19 mm; amoxicillin/clavulanic acid R < 14 mm, S = 19 mm; erythromycin R < 20 mm, S = 20 mm; ciprofloxacin R < 26 mm, S = 26 mm; nalidixic acid R < 26 mm, S = 26 mm; tetracycline R < 30 mm, S = 30 mm; and gentamycin R < 17 mm, S = 17 mm). *Campylobacter jejuni* ATCC 33560 strain was used as quality control.

Of the 127 children studied, 17 (13.4%) harbored *Campylobacter* sp. corresponding 9 (12.9%) to boys and 8 (14.0%) to girls. Asymptomatic excretion of *Campylobacter* species is commonly reported among children from developing countries⁷. In South America, frequencies ranging from 4.9% to 13.8% have been reported⁷. The prevalence of *Campylobacter* isolation rate found in our study (13.4%) was significantly higher to the 6% (*C. jejuni* 4%; *C. coli* 2%) reported in a recent survey conducted in the Ecuadorian capital, city of Quito, among children without diarrhea²⁰. This asymptomatic excretion is an epidemiological feature commonly observed in developing countries⁷, probably associated with poor sanitation conditions and frequent contact with domestic animals considered as reservoirs^{6,7,21}. Furthermore, the high

Table 1 - Distribution of *Campylobacter* by sex

Sex	Number Examined	Positive samples Number (%)	Species isolated Number (%)	
			<i>C. jejuni</i>	<i>C. coli</i>
Male*	70	9 (12.9)	6 (8.6%)	3 (4.3%)
Female*	57	8 (14.0)	3 (5.3%)	5 (8.8%)
Total	127	17 (13.4)	9 (7.1%)	8 (6.3%)

*P>0.005

Table 2 - Distribution of *Campylobacter* by age

Age (months)	Number Examined	% Positive	<i>C. jejuni</i>	<i>C. coli</i>
0-24	28	7.1	0	2
25-60	73	12.3	4	5
>60	26	23.1	5	1
Total	127	13.4	9	8

Table 3 - Antimicrobial resistance of *C. jejuni* and *C. coli* isolated in Loja city, Ecuador

Antimicrobial agent	<i>C. jejuni</i> N=9 %	<i>C. coli</i> N=8 %
Nalidixic acid	77.8	75.0
Ciprofloxacin	77.8	75.0
Erythromycin	0	12.5
Gentamicin	0	0
Ampicillin	0	28.6
Amoxicillin/ clavulanic acid	0	0
Tetracycline	60.0	50.0

prevalence of *Campylobacter* in asymptomatic children may be related to the development of protective immunity due to exposure in early life³.

In Loja region, it was demonstrated that dogs can be a common source of environmental contamination for *C. jejuni* and *C. coli*²². On the other hand, holding small backyard for raising poultry flocks and guinea pigs are popular among Ecuadorian people as meat source. High *Campylobacter* isolation rates have been found among these two types of meat source^{23,24}.

In this study, the isolation frequencies of both species, *C. jejuni* (7.1%) and *C. coli* (6.3%), were similar as it was also the global *Campylobacter* isolation rates among males and females (P>0.005). Although it is noteworthy that there was a higher concentration of *C. jejuni* among boys (8.6%) and *C. coli* (8.8%) among girls. Reasons for this are unknown and as far as we know, this particular

species distribution related to gender has not been described. Some risk factors, like rurality and contact with chickens or chicken meat, have been associated with *C. coli* infection in developed countries²⁵. Further epidemiological studies are necessary in developing countries to explain this issue as well as the causes responsible for its occurrence.

In industrialized countries, infection is more prevalent in children under four years old³ whereas, in developing countries, it is in children under two years old^{7,26}. Despite the fact that asymptomatic colonization with *Campylobacter* is a common feature reported in developing countries⁷, little is known about their age distribution. In a Peruvian survey²⁶, asymptomatic carriers were the most frequent among children <1 year (16.7%) declining up to six years old to 3.8%. The opposite was observed in our study where the lowest isolation rate (7.1%) was found among children <2 years old, occurring an increase in the frequency of isolation as age rises (up to five years old 12.3%; over five years old 23.1%). Further studies are needed to explain this age distribution.

All the *C. jejuni* strains were susceptible to erythromycin, gentamicin, ampicillin and amoxicillin/clavulanic acid, but 77.8% of the isolates were resistant to nalidixic acid and ciprofloxacin. *C. coli* strains were resistant to more antimicrobials than *C. jejuni* strains. Resistant strains were found for nalidixic acid (75%), ciprofloxacin (75%), erythromycin (12.5%) and ampicillin (28.7%), but all were susceptible to gentamicin and amoxicillin/clavulanic acid. EUCAST has not proposed breakpoints for nalidixic acid. Therefore, we homologate the EUCAST breakpoints of ciprofloxacin to define resistance and susceptibility to nalidixic acid. A good correlation among nalidixic acid-resistant and ciprofloxacin-resistant strains was observed,

indicating that nalidixic acid is a good quinolone resistance indicator, therefore, useful to establish surveillance of resistance to these antimicrobials. High resistance to ciprofloxacin was previously reported in Loja city in *C. jejuni* and *C. coli* strains isolated from dog feces²², chicken²³ and chicken livers for human consumption²⁷, thus suggesting that this resistance could also be found with high frequency among strains isolated from human beings. The three ampicillin-resistant strains were susceptible to amoxicillin/clavulanic acid indicating that these resistant strains were beta-lactamase producers, as it has been observed in other Latin American countries²⁸.

ACKNOWLEDGMENTS

This work was supported by Project PRO_CCSAL_1077.

REFERENCES

1. LPSN. List of prokaryotic names with standing in nomenclature: Genus *Campylobacter*. [cited 2016 May 02]. Available from: <http://www.bacterio.net/campylobacter.html>
2. Piccirillo A, Niero G, Calleros L, Pérez R, Naya H, Iraola G. *Campylobacter geochelonis* sp. nov. isolated from the western Hermann's tortoise (*Testudo hermanni hermanni*). *Int J Syst Evol Microbiol*. 2016;66:3468-76.
3. Kaakoush NO, Castaño-Rodríguez N, Mitchell HM, Man SM. Global epidemiology of *Campylobacter* infection. *Clin Microbiol Rev*. 2015;28:687-720.
4. Man SM. The clinical importance of emerging *Campylobacter* species. *Nat Rev Gastroenterol Hepatol*. 2011;8:669-85.
5. Lastovica AJ. Non-*jejuni/coli* *Campylobacter* species and related organisms in poultry, and their relevance in human and animal disease. In: Fonseca BB, Fernández H, Rossi D, editors. *Campylobacter* spp. and related organisms in poultry: pathogen-host interactions, diagnosis and epidemiology. Geneva: Springer; 2016. p.185-206.
6. World Health Organization. The global view of campylobacteriosis: report of an expert consultation, Utrecht, Netherlands, 9-11 July 2012. Geneva: WHO; 2013.
7. Fernández H. *Campylobacter* y campylobacteriosis: una mirada desde América del Sur. *Rev Per Med Exp Salud Publ*. 2011;28:121-7.
8. Epps SV, Harvey RB, Hume ME, Phillips TD, Anderson RC, Nisbet DJ. Foodborne *Campylobacter*: infections, metabolism, pathogenesis and reservoirs. *Int J Environ Res Public Health*. 2013;10:6292-304.
9. Porte L, Varela C, Haecker T, Morales S, Weitzel T. Impact of changing from staining to culture techniques on detection rates of *Campylobacter* spp. in routine stool samples in Chile. *BMC Infect Dis*. 2016;16:196.
10. Varela G, Batthyány L, Bianco MN, Pérez W, Pardo L, Algorta G, et al. Enteropathogens associated with acute diarrhea in children from households with high socioeconomic level in Uruguay. *Int J Microbiol*. 2015;2015:592953.
11. Fernández H, Vera F, Villanueva MP, García A. Occurrence of *Campylobacter* species in healthy well-nourished and malnourished children. *Braz J Microbiol*. 2008;39:56-8.
12. Lee G, Pan W, Peñataro Yori P, Paredes Olortegui M, Tilley D, Gregory M, et al. Symptomatic and asymptomatic *Campylobacter* infections associated with reduced growth in Peruvian children. *PLoS Negl Trop Dis*. 2013;7:e2036.
13. Lehours P, Aladjidi N, Sarlangue J, Mégraud F. Infections à *Campylobacter* chez l'enfant. *Arch Pediatr*. 2012;19:629-34.
14. Anvarinejad M, Amin Shahidi M, Pouladfar GR, Dehyadegari MA, Mardaneh J. *Campylobacter jejuni* bacteremia in a patient with acute lymphocytic leukemia. *Iran Red Crescent Med J*. 2016;18:e23992.
15. McCrackin MA, Helke KL, Galloway AM, Poole AZ, Salgado CD, Marriott BP. Effect of antimicrobial use in agricultural animals on drug-resistant foodborne campylobacteriosis in humans: a systematic literature review. *Crit Rev Food Sci Nutr*. 2016;56: 2115-32.
16. Pan H, Ge Y, Xu H, Zhang J, Kuang D, Yang X, et al. Molecular characterization, antimicrobial resistance and Caco-2 cell invasion potential of *Campylobacter jejuni/coli* from young children with diarrhea. *Pediatr Infect Dis J*. 2016;35:330-4.
17. Fernández H. Increase of *Campylobacter* isolation rates using an enrichment medium. *Rev Microbiol*. 1992;23:5-7.
18. Yamazaki-Matsune W, Taguchi M, Seto K, Kawahara R, Kawatsu K, Kumeda Y, et al. Development of a multiplex PCR assay for identification of *Campylobacter coli*, *Campylobacter fetus*, *Campylobacter hyointestinalis* subsp. *hyointestinalis*, *Campylobacter jejuni*, *Campylobacter lari* and *Campylobacter upsaliensis*. *J Med Microbiol*. 2007;56:1467-73.
19. Société Française de Microbiologie. Comité de l'Antibiogramme. Recommandations 2014. Paris: Société Française de Microbiologie; 2014. [cited 2017 July 28]. Available from: [http://www.sfm-microbiologie.org/UserFiles/files/casfm/CASFM_EUCAST_V1_0_2014\(1\).pdf](http://www.sfm-microbiologie.org/UserFiles/files/casfm/CASFM_EUCAST_V1_0_2014(1).pdf)
20. Vasco G, Trueba G, Atherton R, Calvopiña M, Cevallos W, Andrade T, et al. Identifying etiological agents causing diarrhea in low income Ecuadorian communities. *Am J Trop Med Hyg*. 2014;91:563-9.
21. Fernández H, Kahler K, Salazar R, Ríos M. Prevalence of thermotolerant species of *Campylobacter* and their biotypes in children and domestic birds and dogs in Southern Chile. *Rev Inst Med Trop Sao Paulo*. 1994;36:433-6.
22. Toledo Z, Simaluiza RJ, Ochoa S, Fernández H. Occurrence and antimicrobial susceptibility of *Campylobacter jejuni* and *C. coli* in dog feces from public parks in Southern Ecuador. *Acta Scient Vet*. 2015;43:1284.

23. Ochoa S, Simaluiza RJ, Toledo Z, Fernández H. Frequency and antimicrobial behaviour of thermophilic *Campylobacter* species isolated from Ecuadorian backyard chickens. *Arch Med Vet.* 2016;48:311-4.
24. Graham JP, Vasco K, Trueba G. Hyperendemic *Campylobacter jejuni* in guinea pigs (*Cavia porcellus*) raised for food in a semi-rural community of Quito, Ecuador. *Environ Microbiol Rep.* 2016;8:382-7.
25. Roux F, Sproston E, Rotariu O, MacRae M, Sheppard SK, Bessell P, et al. Elucidating the aetiology of human *Campylobacter coli* infections. *PLoS One.* 2013;8:e64504.
26. Oberhelman RA, Gilman RH, Sheen P, Cordova J, Taylor DN, Zimic M, et al. *Campylobacter* transmission in a Peruvian shantytown: a longitudinal study using strain typing of *Campylobacter* isolates from chickens and humans in household clusters. *J Infect Dis.* 2003;187:260-9.
27. Simaluiza RJ, Toledo Z, Ochoa S, Fernández H. The prevalence and antimicrobial resistance of *Campylobacter jejuni* and *Campylobacter coli* in chicken livers used for human consumption in Ecuador. *J Anim Vet Adv.* 2015;14:6-9.
28. Fernández H, Oval A. Occurrence of *Campylobacter jejuni* and *Campylobacter coli* biotypes and antimicrobial susceptibility in healthy dogs in Southern Chile. *Acta Scient Vet.* 2013;41:1100.